Thrombosis and Haemostasis - McMaster Experts

publication venue for

New approaches to anticoagulation: Oral factor Xa inhibitors 2009
New approaches to oral anticoagulation: Direct thrombin inhibitors 2009
An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice 2005
A latex D-Dimer reliably excludes venous 1999
A trypsin-like platelet protease must generate PAR-1 residues 1-41 and PAR-1 tethered ligand to optimize propagation of platelet activation 1999
Biology of the hypercoagulable state following major trauma 1999
Calcium dependency of conformational changes in the EGF-1 region upon activation, but not active site inhibition, of human FVII 1999
Cleavage of protease-activated receptor-1 (PAR-1) and platelet activation by alpha- and gamma-thrombins 1999
Comparison of inhibition of thrombin generation in newborn, child or adult plasmas by different heparinoids 1999
Comparison of the nonspecific binding of a low molecular of weight heparin (dalteparin) with unfractionated heparin, in pregnant and non-pregnant plasma 1999
Cost effectiveness of the platelet function analyzer (PFA)-100 as a screening test of platelet related primary haemostasis 1999
Effect of chemotherapeutic agents on the regulation of thrombin by endothelial cells 1999
Evidence that change in the kringle-1 glycosylation site contributes to the increased fibrin-specificity of TNK-t-PA relative to t-PA 1999
Evidence that unfractionated heparin and low molecular weight heparin are eliminated by tubular secretion in the rat kidney 1999
Functional analysis of exosites 1 and 2 of thrombin in complex with serine protease inhibitors 1999
Glycoprotein Ib (GPIb) modulates protein tyrosine phosphorylation to enhance platelet protease-activated receptor-1 (PAR-1) cleavage by a-thrombin 1999
Importance of patient population in the frequency of HIT: A comparison of activation and antigen assays 1999
Incomplete neutralization of low molecular weight heparin by protamine results from decreased binding affinity 1999
Influence of factor VIIa concentrates on thrombin generation in full term and preterm neonates 1999
Inhibition of human and rabbit platelet aggregation by recombinant barbourin and barbourin-albumin fusion proteins and derivatives 1999
Low molecular weight heparin for prevention of venous thromboembolism in elective neurosurgery: A metanalysis 1999
Oral anticoagulant therapy (OAT) following heart valve replacement (HVR): Comparison of a daily fixed 2.5 mg with a 5 mg, INR adjusted, dose 1999
Osteoporosis: A potential complication of long term warfarin therapy 1999
Plasma homocysteine measurement: Comparison of three different assay methods in plasma from vascular patients 1999
Predictors of the initial response to warfarin in patients starting oral anticoagulant therapy following heart valve replacement 1999
Prophylaxis of venous thromboembolism in acute medical patients with enoxaparin: An international, randomized, double-blind, placebo-controlled trial 1999
Resistance to activated protein C associated with thrombotic events in pediatric patients with systemic lupus erythematosus 1999
Results of the brat study: Benefits and risks of aspirin on thrombosis in patients undergoing coronary artery bypass surgery: Lack of an aspirin nonresponder effect 1999
Risk factors for venous thromboembolism in patients undergoing elective neurosurgery 1999
Serine base exchange enzyme in commercially available porcine lyophilized platelets: Different effect of unfractionated heparin and low molecular weight heparin 1999
Statins, thrombin suppression, and hypothrombotic states 1999
Surgery in hemophilia B patients with a chemically treated and virus filtered FIX-concentrate (Nanotiv) in continuous infusion 1999
Sustained delivery of therapeutic levels of human factor IX in nude hemophilic mice implanted with encapsulated mouse myoblasts secreting human factor IX 1999
Temporary discontinuation of oral anticoagulants: Role of low molecular weight heparin (dalteparin) 1999
The reaction of neutrophil elastase with plasma heparin cofactor II and a truncated, his-tagged recombinant derivative. 1999
The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg 1999
The role of thrombophilic states in the bleeding tendency of patients with hemophilia 1999
Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: The warfarin optimal duration Italian trial (WODIT) 1999
Unactivated platelets provide factor IX necessary to optimize propagation of tissue factor (TF)-dependent coagulation 1999
Use of an enzyme immunoassay (EIA) for soluble fibrin to exclude the diagnosis of deep vein thrombosis 1999
Use of recombinant factor VIIa (rFVIIa) for bleeding and surgery in patients with Glanzmann thrombasthenia 1999
1-800-NO-CLOTS: A quaternary care solution to a new tertiary care disease: Childhood thrombophilia 1997
A comparison of six months with indefinite duration of oral anticoagulant therapy after a second episode of venous thromboembolism 1997
A cost-effectiveness analysis of low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis 1997
A novel antithrombin-heparin covalent complex with high specific anti-factor Xa and anti-thrombin 1997
A novel antithrombin-heparin covalent complex: Efficacy and safety in rabbits 1997
A randomized comparison of a 5 mg and 10 mg loading dose for the initiation of warfarin therapy 1997
Acquired activated protein C resistance in patients with thrombosis without the factor V Q (506) mutation 1997
Alternative method for detecting APC resistance (APCR) in patients receiving warfarin (W) 1997
Arvin or hirudin reduces the adsorption of Cr-51-platelets and I-125-fibrinogen by the aorta wall immediately after a balloon de-endothelializing injury in vivo 1997
Binding of thrombospheres to chymotrypsin-treated rabbit platelets decreases phosphatidylinositol 4,5-bisphosphate (PIP2) 1997
Blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease ''the ESSENCE trial'' 1997
Both thrombin exosites are required to form a thrombin-heparin-fibrin complex that attenuates thrombin inhibition 1997
Comparison of 3 assays for the measurement of activated protein C resistance (APCR) 1997
Correlation between protein C levels and DNA testing in a large cohort of protein C deficient individuals 1997
Diagnosis of a first dvt in outpatients: Interim analysis of a management based on clinical evaluation and D-dimer (SimpliRED(TM)) results 1997
Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients: A randomised double blind venography study 1997
Evidence for allosteric linkage of exosites 1 and 2 of thrombin 1997
Evidence that vitronectin contributes to non-specific binding of heparin in patient plasma 1997
Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia 1997
Factor V Leiden: A reliable screening assay based on activated partial thromboplastin time (APTT) 1997
Heparin-induced thrombocytopenia, heparin-induced skin lesions, and arterial thrombosis 1997
Hepatitis C-infected hemophiliacs with a negative PCR reaction for hepatitis C RNA 1997
Incidence and diagnosis of neonatal thrombosis associated with umbilical venous catheters 1997
Increased in vivo half-life of recombinant hirudin genetically fused to albumin 1997
Investigation of multimerin in patients with ''platelet low'' type 1 von Willebrand disease 1997
Localization of the thrombin-binding domain on prothrombin fragment 2 1997
Mechanism of tissue plasminogen activator-induced increase in fibrinopeptide A levels in rabbits 1997
Misfolding of the first epidermal growth factor domain results in decreased cellular secretion of factor VII 1997
Mutability of reactive centre loop P4 and P5 residues in human and rabbit antithrombin 1997
Plasma heparin level and coronary patency in patients with acute myocardial infarction treated with a double rt-PA bolus and randomised to two different heparin regimens 1997
Plasmin generated on the (DD)E surface is protected from inactivation by alpha(2)-antiplasmin 1997
Prediction of deep vein thrombosis after elective hip surgery by preoperative haemostatic tests: The ECAT DVT study 1997
Preliminary evaluation of factor VIII/vWF concentrate (FANHDI(R)) for continuous infusion: Stability and bacteriological safety 1997
Protein phosphatase inhibitors inhibit signalling between binding of polymerizing fibrin to chymotrypsin-treated (CT) rabbit platelets and enzymes of phospho-inositide interconversion 1997
Prothrombin fragment 2 modulates thrombin function 1997
Randomized comparison of anticoagulant control by a computer generated system with a manual system 1997
Relationship between cleavage of the 7-transmembrane receptor on platelets and platelet activation by alpha-thrombin 1997
Relationship of factor V Leiden genotype to risk of acute deep vein thrombosis following joint replacement surgery 1997
Subcutaneous low-molecular-weight heparin (LMWH) versus warfarin sodium (WS) for prophylaxis of deep-vein thrombosis (DVT) after total hip or total knee replacement (THR/TKR): An economic perspective 1997
The fibrin-specificity of plasminogen activators is compromised by their interactions with (DD)E 1997
The incidence of venographically proven deep-vein thrombosis in patients undergoing knee arthroscopy 1997
The predictive value of anticardiolipin antibodies in patients with venous thromboembolism. 1997
There is no rationale for stopping aspirin before cardiac surgery 1997
Thrombin-antithrombin (TAT) complexes interact with cytokeratin 18 from rabbit hepatocytes 1997
Ultrastructural localization of multimerin in human endothelial cells 1997
Vasoflux(TM), a novel oligosaccharide with unique antithrombotic properties 1997
Withdrawal of warfarin therapy after deep vein thrombosis: A randomised study on the effects of a very low fixed dose regimen 1997
A COMPARATIVE-STUDY OF HEMATOLOGIC AND COAGULATION ABNORMALITIES INDUCED BY ANABOLIC-STEROIDS IN WEIGHT LIFTERS 1995
A HIRUDIN-ALBUMIN FUSION PROTEIN RETAINS CHARACTERISTICS OF BOTH COMPONENTS 1995
BAT PLASMINOGEN-ACTIVATOR CAUSES LESS FIBRINOGENOLYSIS AND BLEEDING THAN TISSUE-PLASMINOGEN ACTIVATOR IN RATS 1995
CIRCULATORY SURVIVAL OF RECOMBINANT RABBIT ANTITHROMBIN AND DEGLYCOSYLATION MUTANTS 1995
COMPRESSION ULTRASOUND FOR THE DIAGNOSTIC MANAGEMENT OF CLINICALLY SUSPECTED DEEP-VEIN THROMBOSIS 1995
DELETION MUTAGENESIS OF HEPARIN COFACTOR-II - DEFINING THE MINIMAL FUNCTIONAL DOMAINS OF A PLASMA THROMBIN INHIBITOR 1995
EFFECTS OF DERMATAN SULFATE ON ACTIVATED PARTIAL THROMBOPLASTIN TIME DETERMINED WITH 5 DIFFERENT REAGENTS 1995
ESTROGEN THERAPY AND THE RISK OF VENOUS THROMBOEMBOLISM - A REEVALUATION 1995
FACTOR-XA-ANTITHROMBIN-III ENDOGENOUS TO PLASMA - RELATIONSHIP TO PROTHROMBIN ACTIVATION IN-VIVO 1995
FIBRIN CLOT LYSIS BY TISSUE-PLASMINOGEN ACTIVATOR (TPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC-PATIENTS UNDERGOING ORTHOTOPIC LIVER-TRANSPLANTATION 1995
FIBRINOGENOLYSIS AND THROMBIN ACTIVATION AFTER ACCELERATED WEIGHT-ADJUSTED OR CONVENTIONAL ADMINISTRATION OF RT-PA FOR PULMONARY-EMBOLISM 1995
HEPATITIS-E VIRUS-INFECTION IN HEMOPHILIACS 1995
HIRUDIN, BUT NOT HEPARIN, ACCELERATES PHYSIOLOGICAL FIBRINOLYSIS IN A RABBIT CHRONIC VENOUS THROMBOSIS MODEL 1995
IDENTIFICATION OF AN AUTOSOMAL-DOMINANT BLEEDING DISORDER WITH A COMBINED DEFICIENCY OF PLATELET MULTIMERIN AND PLATELET FACTOR-V 1995
IMPROVED DIAGNOSIS BY FLOW-CYTOMETRY OF PREVIOUSLY UNRECOGNIZED PLATELET STORAGE POOL DEFICIENCY IN MYELOPROLIFERATIVE AND MYELODYSPLASTIC DISORDERS 1995
INFLUENCE OF CHANGES IN LIFE-STYLE ON FIBRINOLYTIC PARAMETERS AND RECURRENCY RATE IN PATIENTS WITH VENOUS THROMBOEMBOLISM 1995
INHIBITION OF THROMBIN-INDUCED PLATELET ACTIVATION BY SYNTHETIC ANTI-THROMBINS IN PLASMA 1995
INTRACELLULAR EVENTS DETERMINE THE FATE OF ANTITHROMBIN UTAH 1995
LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) AND COMPRESSION STOCKINGS IN THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) IN NEUROSURGERY 1995
MULTICENTRIC EVALUATION OF HEPARINASE ON APTT, THROMBIN CLOTTING TIME AND A NEW PT REAGENT BASED ON RECOMBINANT HUMAN TISSUE FACTOR 1995
NEONATAL THROMBOSIS - ARE WE DOING THE RIGHT STUDIES 1995
NO CARRYOVER ARTIFACT WHEN USING THE RECOMBINANT THROMBOPLASTIN INNOVIN ON THE AUTOMATED BEHRING FIBRINTIMER-A (BFA) 1995
ONCOSTATIN-M INHIBITS TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR SYNTHESIS IN CULTURE HUMAN ENDOTHELIUM 1995
OUT PATIENT LOW-MOLECULAR-WEIGHT HEPARIN VERSUS IN-HOSPITAL STANDARD HEPARIN FOR THE TREATMENT OF VENOUS THROMBOSIS 1995
POSTDISCHARGE CLINICALLY OVERT THROMBOEMBOLIC EVENTS IN ORTHOPEDIC-SURGERY PATIENTS WITH NEGATIVE VENOGRAPHY 1995
PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER KNEE ARTHROPLASTY - A RANDOMIZED, DOUBLE-BLIND TRIAL, COMPARING A LOW-MOLECULAR-WEIGHT HEPARIN FRAGMENT (ENOXAPARIN) TO WARFARIN 1995
RESISTANCE OF FIBRIN SEALANTS TO PROTEOLYSIS IN A GUINEA-PIG EYE MODEL 1995
RESISTANCE TO ACTIVATED PROTEIN-C (APC-R) IN THROMBOPHILIC PATIENTS - SUMMARY OF RESULTS AFTER 7 MONTHS OF INVESTIGATION 1995
SEROPREVALENCE OF ANTI-HEPATITIS-A (HAV) IGG IN CANADIAN PATIENTS WITH HEMOPHILIA 1995
SITES OF TISSUE FACTOR-DEPENDENT PLASMA COAGULATION SUBJECT TO INHIBITION BY TISSUE FACTOR PATHWAY INHIBITOR 1995
THE CDNA SEQUENCE OF HUMAN ENDOTHELIAL-CELL MULTIMERIN - A NOVEL PROTEIN WITH RGDS, COILED-COIL, AND EGF DOMAINS, AND A CARBOXYL-TERMINUS SIMILAR TO THE GLOBULAR DOMAINS OF COMPLEMENT C1Q 1995
THE DISPLACEMENT OF NONSPECIFICALLY BOUND UNFRACTIONATED HEPARIN FROM PLASMA-PROTEINS PRODUCES AN ANTITHROMBOTIC EFFECT 1995
THE DURATION OF ORAL ANTICOAGULATION AFTER THE 1ST EVENT OF VENOUS THROMBOEMBOLISM - THE DURAC-I TRIAL 1995
THE EFFECT OF ANTITHROMBIN-III AND HEPARIN COFACTOR-II CONCENTRATIONS ON THE ANTICOAGULANT ACTIVITIES OF STANDARD AND LOW-MOLECULAR-WEIGHT HEPARIN IN PLASMA 1995
THE EFFECT OF HEPARIN-BINDING PROTEINS ON THE ANTI-THROMBIN ACTIVITY OF UNFRACTIONATED AND LOW-MOLECULAR-WEIGHT HEPARIN IN PLASMA 1995
THE EFFECT OF LOW-MOLECULAR-WEIGHT HEPARIN ON LA TESTING 1995
THE EFFECTS OF LONG-TERM HEPARIN ON BONE-DENSITY - A PROSPECTIVE CASE-CONTROL STUDY 1995
THE SIGNIFICANCE OF HYPOFIBRINOLYSIS FOR THE RISK OF RECURRENCE OF VENOUS THROMBOEMBOLISM 1995
TREATMENT OF DEEP VENOUS THROMBOSIS WITH LOW-MOLECULAR-WEIGHT HEPARINS - A METAANALYSIS 1995
WARFARIN TREATMENT OF DEEP-VEIN THROMBOSIS COMPLICATING HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IS A RISK FACTOR FOR INITIATION OF VENOUS LIMB GANGRENE - REPORT OF 9 PATIENTS IMPLICATING THE INTERACTING PROCOAGULANT EFFECTS OF 2 ANTICOAGULANT AGENTS 1995
Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis 1995
Low Molecular Weight Heparins (LMWH) in the Treatment of Patients with Acute Venous Thromboembolism 1995
2 CASES OF BERNARD-SOULIER SYNDROME INVESTIGATED BY FLOW-CYTOMETRY 1993
A COMPARISON OF THE PLASMA RECOVERY OF UNFRACTIONATED HEPARIN WITH THAT OF DERMATAN SULFATE IN PATIENTS WITH THROMBOEMBOLIC DISEASE 1993
A DOUBLE-BLIND RANDOMIZED TRIAL OF MINI-DOSE WARFARIN FOR THE PREVENTION OF THROMBOEMBOLISM (TE) IN PATIENTS WITH STAGE-IV BREAST-CANCER 1993
A RANDOMIZED TRIAL COMPARING THE ACTIVATED THROMBOPLASTIN TIME WITH THE HEPARIN ASSAY TO MONITOR HEPARIN-THERAPY IN PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM REQUIRING LARGE DAILY DOSES OF HEPARIN 1993
A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING A LOW-MOLECULAR-WEIGHT HEPARINOID, ORGARAN, WITH ASPIRIN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING SURGERY FOR HIP FRACTURE 1993
AN ENZYMATIC DIAGNOSTIC-TEST FOR HEPARIN-INDUCED THROMBOCYTOPENIA 1993
CHARACTERIZATION OF A HIGHLY POLYMORPHIC TRINUCLEOTIDE SHORT TANDEM REPEAT (STR) WITHIN THE HUMAN ANTITHROMBIN (AT) GENE ON CHROMOSOME-1 - LINKAGE WITH THE AT-HAMILTON ALLELE 1993
CHARACTERIZATION OF A PUTATIVE 45-KDA RABBIT HEPATIC RECEPTOR FOR THROMBIN-ANTITHROMBIN-III (TAT) COMPLEXES 1993
CHRONIC ADMINISTRATION OF ETHANOL INHIBITS ENHANCED RESPONSES TO COLLAGEN OF PLATELETS FROM HYPERCHOLESTEROLEMIC RABBITS 1993
CLOT-BOUND THROMBIN IS PROTECTED FROM INACTIVATION BECAUSE THE SITES OF ANTIPROTEINASE INTERACTION WITH THROMBIN ARE MASKED WHEN THE ENZYME IS BOUND TO FIBRIN 1993
COLOR DOPPLER VS REAL-TIME ULTRASONOGRAPHY IN THE DIAGNOSIS OF POSTOPERATIVE ASYMPTOMATIC DVT 1993
COMPARISON OF THE EFFICACY AND COST OF LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) AND STANDARD HEPARIN (SH) FOR THE PREVENTION OF DEEP-VEIN THROMBOSIS (DVT) FOLLOWING TOTAL HIP-REPLACEMENT (THR) 1993
CONSEQUENCES OF THE INTERACTIONS OF FIBRINOGEN, FIBRIN-I AND GLYCOSAMINOGLYCANS ON PROTHROMBIN ACTIVATION IN HUMAN PLASMA 1993
CONTRAST-MEDIA INDUCES THROMBIN GENERATION DURING PTCA 1993
CONTROL OF ANTICOAGULANT-THERAPY - A CROSS CANADA SURVEY 1993
D-DIMER IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY-EMBOLISM (PE) 1993
DERMATAN SULFATE PREVENTS PROTHROMBIN CONSUMPTION DURING CARDIOPULMONARY BYPASS MORE EFFECTIVELY THAN HEPARIN 1993
DETERMINANTS OF THE ANTITHROMBOTIC RESPONSE TO A STANDARDIZED DOSE OF INTRAVENOUS UNFRACTIONATED HEPARIN IN PATIENTS WITH VENOUS THROMBOEMBOLISM 1993
EFFECTS OF HEPARIN AND DERMATAN SULFATE ON INJURED VESSEL WALL HYPERPLASIA AND VESSEL WALL OCCLUSION 1993
EFFECTS OF SELECTIVE THROMBIN OR FACTOR-XA INHIBITORS ON THE ASSEMBLY OF PLATELET-BOUND PROTHROMBINASE IN PLASMA 1993
EVALUATION OF THE ACCURACY OF IMPEDANCE PLETHYSMOGRAPHY (IPG) AND COMPRESSION ULTRASOUND (CUS) IN OUTPATIENTS WITH SUSPECTED DEEP-VEIN THROMBOSIS (DVT) - A PROSPECTIVE PAIRED DESIGN 1993
EVIDENCE FOR HEPARIN COFACTOR-II (HCII) AS A PHYSIOLOGICAL INHIBITOR OF THROMBIN 1993
EVIDENCE FOR PROTHROMBIN ACTIVATION AND IMPAIRED THROMBIN INHIBITION IN CANCER-PATIENTS 1993
EVIDENCE FOR THE GENERATION OF ELASTASE ACTIVITY IN A PRIMATE MODEL OF DISSEMINATED INTRAVASCULAR COAGULATION (DIC) 1993
EX-VIVO COMPARISON OF THE NONSPECIFIC-BINDING OF UNFRACTIONATED HEPARIN AND ENOXAPARIN TO PLASMA-PROTEINS 1993
FACTOR-VII HAMILTON - A NOVEL TYPE-2 MUTATION LOCATED AT RESIDUE-57 IN THE 1ST EGF DOMAIN OF HUMAN FACTOR-VII 1993
HEPARIN VARIABILITY AND RESISTANCE - COMPARISONS WITH A DIRECT THROMBIN INHIBITOR 1993
HEPARIN-INDUCED THROMBOCYTOPENIA IS MORE COMMON WITH UNFRACTIONATED HEPARIN THAN WITH LOW-MOLECULAR-WEIGHT HEPARIN 1993
HEREDITARY TYPE-II ALPHA(2)MACROGLOBULIN (ALPHA(2)M) DEFICIENCY 1993
INACTIVATION OF FACTOR-VIIIA BY FACTOR-XA 1993
INACTIVATION OF FACTOR-VIIIA BY THROMBIN 1993
INCREASED THROMBIN GENERATION AND ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) AND ANTICARDIOLIPIN ANTIBODIES (ACA) - EVIDENCE FOR A PROTHROMBOTIC STATE 1993
INHIBITION OF FLUID-PHASE AND CLOT-BOUND THROMBIN - EFFECTS OF HEPARIN, HIRUDIN AND A THROMBIN-INHIBITING DECAPEPTIDE (LU-58463) 1993
INR - EVALUATION OF A RECOMBINANT HUMAN TISSUE FACTOR FOR PROTHROMBIN TIME (PT) AND COMPARISON WITH A HUMAN PLACENTA THROMBOPLASTIN EXTRACT 1993
INTERLEUKIN-6 INDUCES HEPATIC VITRONECTIN RNA EXPRESSION IN RATS - A POTENTIAL MECHANISM FOR POSTOPERATIVE ELEVATION OF PLASMA VITRONECTIN IN HUMANS 1993
KINETICS OF PLASMA THROMBIN NEUTRALIZING ACTIVITY IN PATIENTS WITH DEEP-VEIN THROMBOSIS TREATED WITH SUBCUTANEOUS HEPARIN TWICE A DAY 1993
LOW FREE PROTEIN-6 LEVELS IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS 1993
METABOLISM OF RADIOLABELED RABBIT PLASMINOGEN ISOFORMS-I AND-ISOFORMS-II IN RABBITS - PLG-II IS METABOLIZED MORE RAPIDLY THAN PLG-I 1993
OPTIMAL DURATION OF ORAL ANTICOAGULANT-THERAPY - A RANDOMIZED TRIAL COMPARING 4 WEEKS WITH 3 MONTHS OF WARFARIN IN PATIENTS WITH PROXIMAL DEEP-VEIN THROMBOSIS (DVT) 1993
PLASMA HALF-LIFE OF THE ANTI-IIA ACTIVITY OF LOW-MOLECULAR-WEIGHT HEPARINS ASSESSED WITH A SENSITIVE TEST (PTNA) 1993
PLATELET INHIBITION INDUCED BY PLASMINOGEN ACTIVATORS - ROLE OF FIBRINOGEN DEGRADATION PRODUCTS 1993
PLATELET-DERIVED MICROPARTICLES ARE FOUND IN-VIVO IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) 1993
POLYMERIZING FIBRIN DECREASES PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE (PIP(2)) IN CHYMOTRYPSIN-TREATED RABBIT PLATELETS 1993
PROTHROMBIN TIME (PT) - COMPARISON OF 2 RECOMBINANT HUMAN TISSUE FACTOR PREPARATIONS WITH A HUMAN PLACENTA THROMBOPLASTIN EXTRACT 1993
ROLE OF FIBRINOGEN BINDING TO PLATELETS IN ADP-STIMULATED POLYPHOSPHOINOSITIDE METABOLISM OF HUMAN PLATELETS 1993
SIMULTANEOUS INHIBITION OF THROMBIN BY ATIII AND HCII AND PREVENTION OF THROMBUS FORMATION AND GROWTH - RELATIVE EFFECTS OF HEPARIN AND SULODEXIDE 1993
SITE-DIRECTED MUTAGENESIS OF HUMAN ANTITHROMBIN RESIDUE-392 (P2) REVEALS A VARIANT WITH ENHANCED BIOLOGICAL-ACTIVITY 1993
THE COMBINATION OF PRETEST CLINICAL LIKELIHOOD (PCL) AND NONINVASIVE TESTS IMPROVES MANAGEMENT OF OUTPATIENTS WITH SUSPECTED DEEP-VEIN THROMBOSIS (DVT) 1993
THE INTERACTION OF THROMBIN-ANTITHROMBIN-III (TAT) COMPLEXES WITH HEPG2 CELLS UP-REGULATES ANTITHROMBIN-III PRODUCTION 1993
THE POTENTIATION OF FIBRIN POLYMERIZATION BY TISSUE-PLASMINOGEN ACTIVATOR (TPA) 1993
THE RECOVERY OF HEPARIN AND HIRUDIN FROM THE PLASMA OF HEPARIN-RESISTANT PATIENTS 1993
THE ROLE OF (DD)E IN THE KINETICS OF PLASMINOGEN ACTIVATION BY TISSUE-PLASMINOGEN ACTIVATOR 1993
THROMBIN GENERATION DURING CARDIAC-SURGERY - IS HEPARIN THE IDEAL ANTICOAGULANT 1993
TRANSIENT GLOBAL AMNESIA FOLLOWING INTRAVENOUS HEPARIN BOLUS THERAPY IS CAUSED BY HEPARIN-INDUCED THROMBOCYTOPENIA 1993
USE OF ANTITHROMBIN RECOMBINANT DERIVATIVES AND FUSION PRODUCTS TO MAP ITS HEPARIN-BINDING DOMAINS 1993
VALIDATION OF A NEW CRITERIA FOR THE EVALUATION OF BLEEDING DURING ANTITHROMBOTIC THERAPY 1993
WARFARIN AND ITS DRUG FOOD INTERACTIONS - A CRITICAL-APPRAISAL OF THE LITERATURE 1993
ZONES OF ADHESION FORMED BETWEEN PLATELETS AND MATRIX PROTEINS 1993
A simplified procedure for the establishment of APTT therapeutic ranges for heparin (HEP) therapy 1993
A DOUBLE-BLIND RANDOMIZED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID VERSUS UNFRACTIONATED HEPARIN IN THE PREVENTION OF DEEP-VEIN THROMBOSIS IN PATIENTS WITH THROMBOTIC STROKE 1991
ACUTE INVITRO AND CHRONIC INVIVO EFFECTS OF ETHANOL ON AGGREGATION OF PLATELETS FROM CHOLESTEROL-FED RABBITS 1991
ALPHA-2-ANTIPLASMIN SUPPLEMENTATION SELECTIVELY INHIBITS TISSUE PLASMINOGEN ACTIVATOR-INDUCED FIBRINOGENOLYSIS WITHOUT AFFECTING CLOT LYSIS 1991
ANTITHROMBIN-III INDEPENDENT THROMBIN INHIBITORS PREVENT THROMBUS GROWTH MORE EFFECTIVELY THAN HEPARIN - IMPLICATIONS FOR ANTITHROMBOTIC THERAPY 1991
ANTITHROMBIN-III-STOCKHOLM - A POINT MUTATION IN CODON 392 (GLYCINE TO ASPARTIC-ACID) CAUSING IMPAIRED SERINE PROTEASE REACTIVITY 1991
BENEFITS OF PLATELET TRANSFUSIONS IN PREMATURE-INFANTS - A RANDOMIZED CONTROLLED TRIAL 1991
CLINICAL-EXPERIENCES OF A F-XI-CONCENTRATE - POSSIBLE SIDE-EFFECTS 1991
COMPARISON OF ANTITHROMBIN ACTIVITIES OF HEPARIN AND HIRULOG-1 - BASIS FOR IMPROVED ANTITHROMBOTIC PROPERTIES OF DIRECT THROMBIN INHIBITORS 1991
COMPRESSION ULTRASONOGRAPHY (CU) AND IMPEDANCE PLETHYSMOGRAPHY (IPG) FOR THE DETECTION OF VENOUS THROMBOSIS (VT) IN PATIENTS (PTS) WHO HAVE UNDERGONE MAJOR HIP OR KNEE SURGERY 1991
CONTINUOUS REPLACEMENT THERAPY AFTER OPERATIONS IN HEMOPHILIC PATIENTS 1991
DEEP VENOUS THROMBOSIS - NEW NONINVASIVE DIAGNOSTIC-TESTS 1991
DERMATAN SULFATE ANTICOAGULATION DURING CARDIOPULMONARY BYPASS REDUCES BLEEDING AND ELIMINATES THE NEED OF PROTAMINE NEUTRALIZATION 1991
DERMATAN SULFATE INCREASES TPA-INDUCED THROMBOLYSIS WITHOUT INCREASING BLEEDING IN RABBITS 1991
DETERMINANTS OF PLATELET DONOR VARIABILITY IN DIAGNOSTIC TESTING FOR HEPARIN-INDUCED THROMBOCYTOPENIA 1991
DO COAGULATION SCREENING-TESTS DETECT INCREASED GENERATION OF THROMBIN AND PLASMIN IN SICK NEWBORN-INFANTS 1991
EVIDENCE FOR THE PROLONGED CLEARANCE OF ANTI-THROMBIN ACTIVITY OF THE LOW-MOLECULAR-WEIGHT HEPARIN ENOXAPRINE 1991
FIBRIN MODERATES THROMBIN INHIBITION BY ANTITHROMBIN III/HEPARIN BUT NOT THROMBIN INHIBITION BY HEPARIN-COFACTOR II/DERMATAN SULFATE 1991
GLYCOSAMINOGLYCANS DISPLACE ANTICOAGULANTLY-ACTIVE HEPARIN FROM PLASMA-PROTEIN BINDING-SITES 1991
HEPARIN INHIBITS THE AMPLIFICATION OF COAGULATION MEDIATED BY CLOT-BOUND THROMBIN 1991
IDENTIFICATION OF A TETRAPEPTIDE RECOGNITION SEQUENCE FOR THE ALPHA-2-BETA-1 INTEGRIN IN COLLAGEN 1991
IMPAIRED FIBRINOLYTIC-ACTIVITY AND RECURRENT VENOUS THROMBOEMBOLIC DISEASE 1991
INHIBITION OF THE AMPLIFICATION REACTIONS OF COAGULATION BY SITE-SPECIFIC INHIBITORS OF ALPHA-THROMBIN 1991
INHIBITION OF THROMBUS GROWTH IS ACHIEVED MORE EFFECTIVELY BY CATALYZING THROMBIN INHIBITION BY DERMATAN SULFATE HEPARIN COFACTOR-II THAN BY HEPARIN ANTITHROMBIN-III 1991
INVOLVEMENT OF THE NH2-TERMINAL DOMAIN OF ANTITHROMBIN-III IN HEPARIN BINDING AND COMPLEX-FORMATION WITH ALPHA-THROMBIN 1991
PLATELET-INDUCED CLOT RETRACTION INHIBITS STREPTOKINASE BUT NOT TISSUE PLASMINOGEN-ACTIVATOR MEDIATED CLOT LYSIS 1991
POSTOPERATIVE-PATIENT PLASMA INDUCES ENDOTHELIAL-CELL TYPE-I PLASMINOGEN-ACTIVATOR INHIBITOR SYNTHESIS 1991
PROTEOGLYCAN ALTERATIONS IN THE RABBIT CAROTID-ARTERY WALL FOLLOWING DIFFERENT DENUDING INJURIES INVIVO .2. GLYCOSAMINOGLYCANS 1991
PROTEOGLYCANS OF THE RABBIT CAROTID-ARTERY WALL ARE ALTERED AFTER DIFFERENT DENUDING INJURIES INVIVO .1. MORPHOLOGY 1991
SITE-DIRECTED MUTAGENESIS OF ALANINE 382 OF HUMAN ANTITHROMBIN-III (AT-III) 1991
SUSTAINED ANTITHROMBOTIC ACTIVITY AFTER PLASMA-CLEARANCE OF HIRUDIN - COMPARISON WITH HEPARIN 1991
TEFLON CATHETER USE FOR SUBCUTANEOUS HEPARIN ADMINISTRATION DURING PREGNANCY - A RANDOMIZED CROSSOVER STUDY 1991
THE EFFECT OF THROMBIN INHIBITORS ON TISSUE PLASMINOGEN ACTIVATOR-INDUCED THROMBOLYSIS IN A RAT MODEL 1991
THE EFFECTS OF HEPARIN AND HIRUDIN ON THROMBIN BINDING TO THE NORMAL AND THE DEENDOTHELIALIZED RABBIT AORTA SURFACE INVITRO 1991
THE LOW-MOLECULAR-WEIGHT HEPARIN ENOXAPARIN MODERATES FACTOR-VII AND PROTHROMBIN CONSUMPTION ASSOCIATED WITH ELECTIVE KNEE SURGERY 1991
THE PERINATAL CIRCULATING ANTICOAGULANT IN MOTHER AND FETUS IS A SMALL DERMATAN SULFATE PROTEOGLYCAN 1991
THE RATE OF FIBRINOPEPTIDE-B RELEASE MODULATES THE RATE OF CLOT FORMATION - A STUDY WITH AN ACQUIRED INHIBITOR TO FIBRINOPEPTIDE-B RELEASE 1991
THROMBIN REMAINS BOUND TO SOLUBLE FIBRIN DEGRADATION PRODUCTS AND IS PARTIALLY PROTECTED FROM INHIBITION BY HEPARIN-ANTITHROMBIN .3. 1991
THROMBIN-ANTITHROMBIN III COMPLEXES (TAT) IN PULMONARY-EMBOLISM (PE) 1991
ACTIVATION OF PLASMA FACTOR-V BY THROMBIN AND FACTOR-XA - INHIBITION BY HIRUDIN AND THE SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY TO ANTITHROMBIN-III 1989
ALPHA-2-MACROGLOBULIN MAY PROVIDE PROTECTION FROM THROMBOEMBOLIC EVENTS IN ANTITHROMBIN-III DEFICIENT CHILDREN 1989
CLINICAL EFFECT OF DDAVP DURING SURGERY OR OTHER PROCEDURES IN PATIENTS WITH HEMOSTATIC DISORDERS 1989
DIAGNOSIS OF PROTEIN-C (PC) DEFICIENCY IN PATIENTS ON ORAL ANTICOAGULATION (OA) 1989
FIBRIN CLOT LYSIS BY THROMBOLYTIC AGENTS IS IMPAIRED IN THE NEWBORN 1989
HEPARIN, DERMATAN SULFATE AND THE SYNTHETIC PENTASACCHARIDE WITH HIGH-AFFINITY TO ATIII INHIBIT COAGULATION BY DELAYING PROTHROMBINASE FORMATION 1989
HYPERCOAGULABLE STATE FOLLOWING WARFARIN WITHDRAWAL IN PATIENTS GIVEN SECONDARY PROPHYLAXIS WITH ORAL ANTICOAGULATION AFTER MYOCARDIAL-INFARCTION 1989
IMMUNOLOGICAL FUNCTION IN HEMOPHILIACS TREATED WITH PLASMA DERIVED META-AB PURIFIED FVIII CONCENTRATE 1989
OPTIMAL THERAPEUTIC RANGE FOR ORAL ANTICOAGULANT-THERAPY 1989
RELATIONSHIP BETWEEN ANTI-FACTOR-XA LEVEL AND CLINICAL OUTCOME IN PATIENTS RECEIVING ENOXAPARINE TO PREVENT DEEP-VEIN THROMBOSIS AFTER HIP-REPLACEMENT 1989
THROMBOLYTIC THERAPY FOR VENOUS THROMBOSIS AND PULMONARY-EMBOLISM 1989
A DOUBLE-BLIND RANDOMIZED TRIAL OF ORG-10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN THE PREVENTION OF DEEP-VEIN THROMBOSIS IN PATIENTS WITH THROMBOTIC STROKE 1987
ALPHA-2-MACROGLOBULIN IS A MORE IMPORTANT INHIBITOR OF THROMBIN IN INFANT PLASMA THAN IN ADULT PLASMA 1987
CANCER-CHEMOTHERAPY AND THROMBOSIS 1987
DEEP-VEIN THROMBOSIS PROPHYLAXIS IN SURGICALLY TREATED FRACTURED HIP PATIENTS 1987
ENDOTHELIAL BASEMENT-MEMBRANE PROTEOGLYCAN (PG) ALTERATIONS IN DEOXYCORTICOSTERONE (DOCA)-NACL-INDUCED HYPERTENSIVE RAT MESENTERIC-ARTERIES 1987
HEPARIN IS NOT AN EFFICIENT INHIBITOR OF THE FACTOR XA-DEPENDENT ACTIVATION OF FACTOR-V AND FACTOR-VIII 1987
IDENTIFICATION OF A NEUTROPHIL ELASTASE CLEAVAGE SITE ON THE A-ALPHA-CHAIN OF PRIMATE FIBRINOGEN 1987
INCREASED SULFATION IMPROVES THE ABILITY OF VESSEL WALL GLYCOSAMINOGLYCANS TO REGULATE THROMBIN ACTIVITY AND PROTHROMBIN ACTIVATION IN PLASMA 1987
INCREASED SULFATION INCREASES THE BLEEDING SIDE-EFFECTS OF GLYCOSAMINOGLYCANS 1987
INDUCED ANTIBODIES TO VONWILLEBRAND-FACTOR (VWF) 1987
PLASMA-ARTIFICIAL SURFACE INTERACTIONS - ROLE OF CONTACT AND FIBRINOLYTIC SYSTEMS 1987
PLATELET-FIBRIN CLOTS FORMED BY THROMBIN SELECTIVELY RETAIN PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE (PIP2) 1987
THE BEHAVIOR OF RABBIT PLASMINOGEN AT THE LUMINAL SURFACE OF RABBIT AORTA INVIVO BEFORE AND AFTER BALLOON-CATHETER INJURY 1987
THE EFFECTS OF SULFATED POLYSACCHARIDES ON INHIBITION OF THROMBOSIS INDUCED BY DIFFERENT STIMULI 1987
THE POSTNATAL-DEVELOPMENT OF THE COAGULATION SYSTEM IN THE PREMATURE-INFANT 1987
THE RELATIVE EFFICACY OF GENETIC-ANALYSIS AND COAGULATION-TESTING IN THE DIAGNOSIS OF CARRIERS OF HEMOPHILIA-A 1987
CANCER CHEMOTHERAPY AND THROMBOSIS 1987
DEEP VEIN THROMBOSIS PROPHYLAXIS IN SURGICALLY TREATED FRACTURED HIP PATIENTS 1987
ENHANCED THROMBIN-INDUCED AGGREGATION AND INOSITOL TRISPHOSPHATE FORMATION OF PLATELETS FROM SPONTANEOUSLY HYPERCHOLESTEROLEMIC RATS 1987
PLASMA-ARTIFICIAL SURFACE INTERACTIONS; ROLE OF CONTACT AND FIBRINOLYTIC SYSTEMS 1987
THE RELATIVE EFFICACY OF GENETIC ANALYSIS AND COAGULATION TESTING IN THE DIAGNOSIS OF CARRIERS OF HEMOPHILIA A 1987
A COMPARISON OF ORAL AND INTRAVENOUS DIPYRIDAMOLE TO PRESERVE PLATELETS FOLLOWING CORONARY-BYPASS SURGERY 1985
A DERMATAN SULFATE-LIKE ANTICOAGULANT IN THE FETAL LAMB AFTER ADMINISTRATION OF PK-10169 TO THE EWE 1985
COMPARISON OF BINDING-PROPERTIES OF THROMBIN AND ANTITHROMBIN-III (ATIII) BY RABBIT THORACIC AORTA ENDOTHELIUM AND SUBENDOTHELIUM INVITRO 1985
COMPARISON OF RESULTS OF HEPARIN ASSAYS IN PATIENTS WITH VENOUS THROMBOSIS TREATED WITH INTRAVENOUS HEPARIN MONITORED WITH THE APTT 1985
CONTRIBUTIONS OF ANTI-FACTOR-XA AND ANTI-THROMBIN ACTIVITIES OF GLYCOSAMINOGLYCANS (GAGS) TO THEIR ANTICOAGULANT AND ANTITHROMBOTIC PROPERTIES 1985
DEVELOPMENT AND CLINICAL-EVALUATION OF AN AUTOMATED-ASSAY FOR EFFECTIVE HEPARIN ACTIVITY 1985
EFFECTS OF INTERMITTENT PNEUMATIC CALF COMPRESSION ON POSTOPERATIVE THROMBIN AND PLASMIN ACTION 1985
EVIDENCE FOR SIMULTANEOUS CLEAVAGE OF THE A-ALPHA-CHAIN AND B-BETA-CHAINS IN THE EARLY STAGES OF PLASMIN DIGESTION OF FIBRINOGEN 1985
EVIDENCE THAT INTACT HUMAN-PLATELETS PROVIDE FACTOR VII-LIKE ACTIVITY FOR THE ACTIVATION OF FACTOR-X BY THE EXTRINSIC COAGULATION PATHWAY 1985
HEMORRHAGIC COMPLICATIONS OF LONG-TERM ANTICOAGULANT-THERAPY 1985
HEPARIN AND PENTOSAN POLYSULFATE INHIBIT THE FORMATION OF PROTHROMBINASE AND TENASE COMPLEXES IN PLASMA DEPLETED OF BOTH ANTITHROMBIN III (ATIII) AND HEPARIN COFACTOR-II (HCII) 1985
IDENTIFICATION OF A SPECIFIC LEUKOCYTE ELASTASE CLEAVAGE SITE ON THE FIBRINOGEN A-ALPHA-CHAIN 1985
LONG-TERM SEQUELAE OF CALF VEIN-THROMBOSIS (CVT) TREATED WITH HEPARIN OR LOW-DOSE STREPTOKINASE 1985
POSTNATAL-DEVELOPMENT OF THE COAGULATION SYSTEM IN THE FULL-TERM INFANT 1985
RATIONALE BEHIND THE DEVELOPMENT OF LOW-MOLECULAR WEIGHT HEPARIN DERIVATIVES 1985
RELATIONSHIP BETWEEN THROMBOEMBOLIC COMPLICATIONS AND INTENSITY OF TREATMENT DURING LONG-TERM PROPHYLAXIS WITH ORAL ANTICOAGULANTS FOLLOWING DEEP-VEIN THROMBOSIS (DVT) 1985
STIMULATION OF THE PLATELET-RELEASE REACTION BY THE IONOPHORE A23187 INVOLVES INOSITOL TRISPHOSPHATE (IP3) 1985
STUDIES ON THE DIAGNOSIS AND PATHO-PHYSIOLOGY OF HEPARIN-INDUCED THROMBOCYTOPENIA 1985
SYSTEMIC FIBRINOLYSIS IN VENOUS THROMBOSIS PATIENTS TREATED WITH RECOMBINANT TISSUE-TYPEPLASMINOGEN ACTIVATOR 1985
TAILORING PROPHYLAXIS TO THE RISK OF THROMBOSIS AND BLEEDING 1985
THE DURATION OF ORAL ANTICOAGULATION (OA) AFTER DEEP-VEIN THROMBOSIS (DVT) - A RANDOMIZED STUDY 1985
THE EFFECT OF EPINEPHRINE ON ADP-INDUCED CHANGES IN RABBIT PLATELET PHOSPHOINOSITIDE METABOLISM 1985
THE HEMORRHAGIC AND ANTITHROMBOTIC EFFECTS OF DERMATAN SULFATE 1985
THE ROLE OF THE LIPOXYGENASE PATHWAY IN THE MECHANISM OF ACTION OF NAFAZATROM 1985
THROMBOLYSIS AND FIBRINOLYTIC PARAMETERS DURING HEPARIN TREATMENT OF DEEP-VEIN THROMBOSIS (DVT) 1985
UNIQUE CLEAVAGE OF FIBRINOGEN BY HUMAN-LEUKOCYTE ELASTASE 1985
USE OF POLYCLONAL ANTIBODIES TO FACTOR-VII FOR THE DETECTION OF MONOCLONAL-ANTIBODIES TO FACTOR-VII 1985
A COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE APPROACHES FOR LONG-TERM TREATMENT OF PROXIMAL VENOUS THROMBOSIS 1983
A RANDOMIZED TRIAL OF DIAGNOSTIC STRATEGIES FOR SYMPTOMATIC DEEP-VEIN THROMBOSIS 1983
A RANDOMIZED TRIAL OF SEQUENTIAL PNEUMATIC LIMB COMPRESSION IN THE PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING ELECTIVE HIP-SURGERY 1983
ADP-INDUCED CHANGES IN PHOSPHOLIPIDS OF RABBIT AND HUMAN-PLATELETS 1983
COMPARATIVE EFFECTS OF 2 LOW-MOLECULAR WEIGHT (LMW) HEPARINS, PREPARED BY DIFFERENT FRACTIONATION TECHNIQUES, IN ANIMAL EXPERIMENTAL-MODELS 1983
DOPPLER ULTRASONOGRAPHY IN PATIENTS WITH CLINICALLY SUSPECTED DEEP-VEIN THROMBOSIS - IMPROVED SENSITIVITY BY INCLUSION OF POSTERIOR TIBIAL VEIN EXAMINATION SITE 1983
EFFECTS OF ASPIRIN AND SALICYLATE ON PLATELET-FUNCTION 1983
FAILURE OF SULOCTIDIL TO PREVENT DEEP VENOUS THROMBOSIS IN NEUROSURGICAL PATIENTS 1983
FIBRIN PROTEOLYSIS AND PLATELET ALPHA-GRANULE RELEASE IN PRE-ECLAMPSIA AND ECLAMPSIA 1983
HEPARIN SULFATE AND DERMATAN SULFATE INHIBIT THROMBIN GENERATION IN PLASMA 1983
LONG-TERM TREATMENT OF VENOUS THROMBOSIS WITH LESS INTENSE ANTICOAGULATION 1983
LOW-MOLECULAR WEIGHT HEPARIN DOES NOT CROSS THE PLACENTA 1983
OUTCOME OF ABNORMAL IMPEDANCE PLETHYSMOGRAPHY RESULTS IN PATIENTS WITH PROXIMAL VEIN-THROMBOSIS - FREQUENCY OF RETURN TO NORMAL 1983
PLATELET SURVIVAL AND BETATHROMBOGLOBULIN AFTER HETEROGRAFT MITRAL-VALVE REPLACEMENT - EFFECT OF SULOCTIDIL 1983
PULMONARY ANGIOGRAPHY, VENTILATION SCANNING AND VENOGRAPHY IN PATIENTS WITH CLINICALLY SUSPECTED PULMONARY-EMBOLISM AND ABNORMAL PERFUSION SCANS 1983
THE BIOLOGICAL RELEVANCE OF PLATELET-ASSOCIATED IGG 1983
THE DISPARITY BETWEEN HEPARIN-INDUCED BLEEDING AND COAGULATION AND PLATELET TESTS 1983
THE REGULATION OF PLATELET ENDOTHELIAL CELL-ADHESION BY 2 ARACHIDONIC-ACID METABOLITES 1983
A RANDOMIZED CLINICAL-TRIAL OF TITRATED DOSE SUBCUTANEOUS HEPARIN VERSUS WARFARIN IN THE LONG-TERM TREATMENT OF PATIENTS WITH VENOUS THROMBOSIS 1981
ABNORMALITIES IN PLATELET ARACHIDONIC-ACID METABOLISM IN CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA 1981
ALTERATIONS OF PLATELET MORPHOLOGY IN HUMAN ISCHEMIC-HEART-DISEASE AND IN AN ACUTE THROMBOSIS RABBIT MODEL 1981
Abnormalities In Platelet Arachidonic Acid Metabolism In Chronic Idiopathic Thrombocytopenic Purpura 1981
BETATHROMBOGLOBULIN AND FIBRINOPEPTIDE-A IN EXERCISE-INDUCED MYOCARDIAL ISCHEMIA 1981
Changes In Triphosphatidylinositol Metabolism During PGE1- Induced Shape Change Of Washed Rabbit Platelets 1981
DIAGNOSIS OF DEEP-VEIN THROMBOSIS - THE CASE FOR NON-INVASIVE TESTING 1981
DISSEMINATED INTRAVASCULAR COAGULATION COMPLICATING THE PERINATAL DROPPED-DEAD SYNDROME - LACK OF INFLUENCE OF CARDIOPULMONARY RESUSCITATION 1981
Disseminated Intravascular Coagulation Complicating The Perinatal “Dropped-Dead” Syndrome: Lack Of Influence Of Cardio-PulmoNary Resuscitation 1981
Heparin Associated Thrombocytopenia Is Not A Typical Drug Induced Thrombocytopenia 1981
Inactivation Of Thrombin By Antithrombin III In The Presence Of Surface Bound Heparin 1981
KINETICS OF ADSORPTION OF PROTEINS FROM HUMAN-PLASMA ONTO FOREIGN SURFACES 1981
Kinetics Of Adsorption Of Proteins From Human Plasma Onto Foreign Surfaces 1981
NEED FOR LARGE (BUT SIMPLE) TRIALS 1981
PLASMA AND URINE BETATHROMBOGLOBULIN CONCENTRATION IN DEEP-VEIN THROMBOSIS 1981
PLASMINOGEN ACTIVATION IN NORMAL INDIVIDUALS AND PATIENTS WITH THROMBOTIC TENDENCY 1981
RELATIVE CONTRIBUTIONS OF THROMBIN AND ANTITHROMBIN-III AFFINITIES OF HEPARIN FRACTIONS TO THE RATE OF INACTIVATION OF THROMBIN BY ANTITHROMBIN-III 1981
SEX-RELATED DIFFERENCES IN ASPIRIN PHARMACOKINETICS FOLLOWING IV-INJECTION IN RABBITS 1981
THE CONTRIBUTION OF INCREASED FIBRINOLYSIS INDUCED BY INTERMITTENT PNEUMATIC COMPRESSION OF THE LEGS IN THE PREVENTION OF DEEP-VEIN THROMBOSIS 1981
THE EFFECT OF ANTI-PLATELET DRUGS ON PLATELET SURVIVAL-TIME AND BETATHROMBOGLOBULIN IN CORONARY-ARTERY DISEASE 1981
THE USE OF NON-INVASIVE TESTING AND VENOGRAPHY FOR THE DIAGNOSIS OF ACUTE RECURRENT DEEP-VEIN THROMBOSIS 1981
THROMBOXANE B2 AND BETATHROMBOGLOBULIN IN SYMPTOMATIC CORONARY-ARTERY DISEASE 1981
The Effects Of Heparin On The Activation Of Factor X And Prothrombin In Antithrombin III-Depleted Plasma 1981
The Fate Of Surface Bound Heparin And The Long Term Thromboresistance Of Heparinized Materials 1981
The Influence Of Heparin, Phospholipid And Platelets On The Thrombin Or Factor Xa Inactivation By Antithrombin III 1981
The Lack Of Relationship Between Anti-Xa Activity And Antithrombotic Activity Of Low Molecular Weight Heparin 1981
VIRUS-INDUCED THROMBOCYTOPENIA - THE ROLE OF VIRAL HEMOLYSIN AND NEURAMINIDASE 1981
Viral Replication And Platelet Adhesiveness To Vascular Endothelium 1981
Thrombotic Thrombocytopenic Purpura: Mechanism for Effectiveness of Plasmapheresis 1979
A Comparison of Two Assays for Platelet Antibodies 1979
Thrombotic Thrombocytopenic Purpura: Mechanism for Effectiveness of Plasmapheresis 1979
FIBRINOPEPTIDE-A (FPA) LEVELS IN VENOUS THROMBOSIS AND PULMONARY-EMBOLISM BEFORE AND DURING ANTICOAGULANT THERAPY 1977
INCREASED HEPARIN CLEARANCE IN EXPERIMENTAL PULMONARY-EMBOLISM 1977
The Biphasic Effect of Sulfinpyrazone on Platelet Function 1977
The Effect of a Combination of Sulfinpyrazone (SUL) & Aspirin (ASA) on Platelet Survival & Thrombus Size in an Experimental Thrombosis Model 1977
Vasoactive Substances in Pulmonary Embolism 1977
Machine Learning-Based Predictive Models for Patients with Venous Thromboembolism: A Systematic Review. 124:1040-1052. 2024
Time Trends and Excess Mortality Compared to Population Controls after a First-Time Pulmonary Embolism or Deep Vein Thrombosis. 2024
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper. 124:770-777. 2024
Outcomes of Patients with a Mechanical Heart Valve and Poor Anticoagulation Control on Warfarin. 124:613-624. 2024
Patterns and Persistence of Anticoagulant Use in the Treatment of Venous Thromboembolism: Insights from South Korea. 124:163-165. 2024
Risk Factors for Venous Thromboembolism in Women of Childbearing Age. 123:1069-1071. 2023
Anticoagulant Management and Outcomes in Nontraumatic Intracranial Hemorrhage Complicated by Venous Thromboembolism: A Retrospective Chart Review. 123:966-975. 2023
Recurrent Thrombosis and Bleeding in Patients with Cancer-Associated Venous Thromboembolism Receiving Anticoagulation: Are These Modifiable Risk Factors for Mortality?. 123:487-489. 2023
Direct Oral Anticoagulants in the Very Elderly. 123:377-379. 2023
Protocol for a Systematic Review and Individual Participant Data Meta-Analysis of Randomized Trials of Screening for Atrial Fibrillation to Prevent Stroke. 123:366-376. 2023
BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial. 123:027-039. 2023
How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review. 123:006-015. 2023
Prevention of the Postthrombotic Syndrome with Anticoagulation: A Narrative Review. 122:1255-1264. 2022
State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. 122:1279-1287. 2022
Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis. 122:1186-1197. 2022
Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. 122:998-1005. 2022
Stroke and Thromboembolism in Patients with Heart Failure and Sinus Rhythm: A Matter of Risk Stratification?. 122:871-878. 2022
Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. 122:857-866. 2022
Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2. 122:304-307. 2022
Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: Fraternal—Not Identical—Twins. 121:1558-1561. 2021
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. 121:1684-1695. 2021
Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. 121:1677-1680. 2021
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. 121:1400-1408. 2021
“Part of the Ritual”: Exploring Patient and Physician Decision Making Regarding Anticoagulation Use in Obstetric Antiphospholipid Syndrome. 121:1353-1360. 2021
Patient- and Health-Care-Provider-Reported Outcomes to Consider in Research on Pregnancy-Associated Venous Thromboembolism. 121:1228-1236. 2021
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. 121:1008-1020. 2021
Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. 121:1097-1106. 2021
The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. 121:992-1007. 2021
Anticoagulant Treatment of COVID-19 as Early as Possible—Sulodexide and Perspectives. 121:849-853. 2021
Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters. 121:690-693. 2021
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. 121:518-528. 2021
Direct Oral Anticoagulant Dosing in Extremes of Body Weight: Time to Revisit the Guidelines?. 121:118-120. 2021
Venous Thromboembolism in COVID-19. 120:1642-1653. 2020
Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review. 120:1323-1329. 2020
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. 120:1147-1158. 2020
Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. 120:1143-1146. 2020
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. 120:1004-1024. 2020
Plasma Levels of Protein Z in Ischemic Stroke: A Systematic Review and Meta-Analysis. 120:815-822. 2020
Refining Risk Prediction for Recurrent Venous Thromboembolism: Can We Do Better?. 120:725-727. 2020
Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. 120:847-856. 2020
Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 120:484-494. 2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. 120:515-524. 2020
Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer. 120:194-196. 2020
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. 120:132-140. 2020
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment. 120:014-026. 2020
PBMCs-Derived microRNA Signature as a Prethrombotic Status Discriminator in Stable Coronary Artery Disease. 120:121-131. 2020
Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with Postthrombotic Syndrome. 119:1897-1899. 2019
Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. 119:1675-1685. 2019
Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. 119:1365-1372. 2019
Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. 119:992-999. 2019
Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. 119:981-991. 2019
Neutrophil and Monocyte Counts in Heparin-Induced Thrombocytopenia. 119:941-951. 2019
Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. 119:689-694. 2019
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. 119:576-585. 2019
Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral–Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial. 119:633-644. 2019
Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. 119:668-674. 2019
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. 119:461-466. 2019
Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study. 119:368-376. 2019
Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale. 119:500-507. 2019
Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis. 119:328-339. 2019
Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. 119:319-327. 2019
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations. 119:014-038. 2019
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. 118:2188-2188. 2018
In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. 118:1895-1901. 2018
Erratum to: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant who Need an Elective Surgery or Procedure: Design and Rationale. 118:1679-1680. 2018
Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study. 118:1646-1655. 2018
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. 118:1439-1449. 2018
Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. 118:1001-1008. 2018
International Normalized Ratio Targets for Left-Sided Mechanical Valve Replacement. 118:906-913. 2018
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. 118:842-851. 2018
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. 118:S23-S33. 2018
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. 118:437-450. 2018
Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. 118:229-250. 2018
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. 117:2406-2414. 2017
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.. 117:2045-2052. 2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. 117:2135-2145. 2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial.. 117:2135-2145. 2017
Accumulating data on rivaroxaban for venous thromboembolism in clinical practice. 117:1840-1840. 2017
Comparison of clinical probability-adjusted D-dimer and age-adjusted D-dimer interpretation to exclude venous thromboembolism. 117:1937-1943. 2017
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. 117:2045-2052. 2017
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. 117:1841-1847. 2017
Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. 117:1509-1517. 2017
Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done?. 117:2213-2214. 2017
NOACs for treatment of venous thromboembolism in clinical practice. 117:1317-1325. 2017
New developments in anticoagulants: Past, present and future. 117:1283-1288. 2017
Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. 117:491-499. 2017
Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. 117:589-594. 2017
Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review. 117:1868-1874. 2017
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. 117:415-421. 2017
Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. 117:382-389. 2017
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. 117:1023-1030. 2017
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale. 117:2415-2424. 2017
The role of microRNAs in prethrombotic status associated with coronary artery disease. 117:429-436. 2017
Venous thromboembolism: Past, present and future. 117:1219-1229. 2017
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. 116:1159-1164. 2016
Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). 116:1172-1179. 2016
Venous thromboembolism: A Call for risk assessment in all hospitalised patients. 116:777-779. 2016
Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. 116:813-822. 2016
Heparin-induced thrombocytopenia in 2017 and beyond. 116:781-782. 2016
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. 116:879-890. 2016
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. 115:291-298. 2016
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. 115:257-270. 2016
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. 116:241-250. 2016
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. 116:544-553. 2016
D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. 115:921-930. 2016
Direct oral anticoagulants (DOACs) and pregnancy: A plea for better information. 116:590-591. 2016
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. 116:747-753. 2016
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. 115:809-816. 2016
Erratum to Fischer et al. “Inhibitor development in nonsevere haemophilia across Europe” (Thromb Haemost 2015; 114: 670-675). 115:684-684. 2016
Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. 115:89-98. 2016
Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. 116:659-668. 2016
Matching genes with constitution and environment. 116:592-594. 2016
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. 115:685-711. 2016
Spotlight on real-world evidence for the treatment of DVT: XALIA. 116:S41-S49. 2016
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. 116:S33-S40. 2016
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. 115:1240-1248. 2016
The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. 116:480-485. 2016
The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding. 116:87-95. 2016
Treatment of acute pulmonary embolism with dabigatran versus warfarin. 116:714-721. 2016
Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure. 115:533-542. 2016
Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. 113:1193-1202. 2015
Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. 113:1278-1288. 2015
‘Real world’ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. 113:1159-1161. 2015
Inhibitor development in haemophilia according to concentrate. 113:968-975. 2015
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. 113:958-967. 2015
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. 113:625-632. 2015
Scoring systems for heparin-induced thrombocytopenia (HIT): Whither now?. 113:437-438. 2015
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. 114:1290-1298. 2015
Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. 114:933-944. 2015
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 114:198-205. 2015
Edoxaban for treatment of venous thromboembolism in patients with cancer. 114:1268-1276. 2015
Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. 114:56-64. 2015
Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. 114:768-777. 2015
Inhibitor development in non-severe haemophilia across Europe. 114:670-675. 2015
Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. 114:1049-1057. 2015
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. 114:1113-1126. 2015
Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. 114:819-825. 2015
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. 114:150-157. 2015
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. 114:645-650. 2015
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. 111:94-102. 2014
Comment on: Editorial by Husted et al. “Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel”. 112:841-841. 2014
Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. 112:412-418. 2014
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). 112:213-225. 2014
Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. 112:1120-1128. 2014
Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. 112:465-473. 2014
Evidence and Clinical Judgment: Vena cava filters. 111:618-624. 2014
External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). 112:692-699. 2014
Graduated compression stockings to treat acute leg pain associated with proximal DVT. 112:1137-1141. 2014
HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux- induced HIT. 112:1319-1322. 2014
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. 112:924-931. 2014
Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. 111:10-13. 2014
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. 112:233-239. 2014
New oral anticoagulant agents – general features and outcomes in subsets of patients. 111:575-582. 2014
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. 112:798-807. 2014
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. 112:781-782. 2014
Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. 112:79-86. 2014
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. 112:918-923. 2014
Patient outcomes using the European label for dabigatran. 112:933-942. 2014
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. 111:1141-1152. 2014
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. 111:172-179. 2014
Solving the mystery of excessive warfarin-induced bleeding: A personal historical perspective. 112:853-856. 2014
Thrombosis: A major contributor to global disease burden. 112:843-852. 2014
Accuracy of emergency physician–performed ultrasonography in the diagnosis of deep-vein thrombosis. 109:137-145. 2013
Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets. 109:1016-1024. 2013
Dabigatran monitoring made simple?. 110:393-395. 2013
Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies. 110:205-212. 2013
General mechanisms of coagulation and targets of anticoagulants (Section I). 109:569-579. 2013
High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. 110:184-190. 2013
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. 110:1152-1163. 2013
Interactions of heparin and a covalently-linked antithrombin-heparin complex with components of the fibrinolytic system. 110:1180-1188. 2013
Non-OO blood type influences the risk of recurrent venous thromboembolism. 110:1172-1179. 2013
Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). 109:769-786. 2013
Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. 109:328-336. 2013
Procoagulants for management of bleeding with the new oral anticoagulants. 110:01-01. 2013
Transient pseudothrombocytopenia associated with immune heparin-induced thrombocytopenia complicated by pulmonary embolism. 109:971-973. 2013
Vitamin K antagonists in heart disease: Current status and perspectives (Section III). 110:1087-1107. 2013
Zinc: An important cofactor in haemostasis and thrombosis. 109:421-430. 2013
A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. 107:201-214. 2012
Contra: “Bridging anticoagulation is needed during warfarin interruption when patients require elective surgery”. 108:210-212. 2012
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. 108:672-682. 2012
Home-monitoring of oral anticoagulation vs. dabigatran. 108:647-653. 2012
Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data. 108:872-875. 2012
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. 108:493-498. 2012
Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. 108:876-886. 2012
Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. 107:8-14. 2012
Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. 108:1228-1235. 2012
Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins. 107:972-984. 2012
Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. 107:1027-1034. 2012
Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder. 107:726-734. 2012
The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by “true” heparin-induced thrombocytopenia. 107:998-1000. 2012
The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. 108:394-396. 2012
A prospective cohort study of light transmission platelet aggregometry for bleeding disorders: Is testing native platelet-rich plasma non-inferior to testing platelet count adjusted samples?. 106:675-682. 2011
A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. 105:232-238. 2011
BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. 106:1203-1214. 2011
Clopidogrel in acute coronary syndromes: Where are we now?. 105:766-773. 2011
Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. 106:571-584. 2011
Need for a new paediatric post thrombotic sequelae outcome measure for non-extremity thrombosis. 105:1105-1106. 2011
Platelet activation in the pathogenesis of obesity and vascular disease. 106:567-568. 2011
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. 105:444-453. 2011
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. 106:429-438. 2011
Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation. 105:586-596. 2011
Venous thromboembolism in patients with symptomatic atherosclerosis. 106:1095-1102. 2011
Safety of thrombolysis in cerebral venous thrombosis A systematic review of the literature. 104:1055-1062. 2010
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. 104:1150-1157. 2010
Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. 103:481-483. 2010
Bone mineral density in haemophilia patients. 103:596-603. 2010
Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va. 103:910-919. 2010
Evidence and clinical judgment: Treatment of cerebral vein thrombosis. 103:1109-1115. 2010
Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. 104:1071-1072. 2010
HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. 103:83-96. 2010
Heyde’s syndrome: From controversy to mainstream. 103:251-253. 2010
High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis. 103:123-128. 2010
Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys. 104:837-844. 2010
New oral anticoagulants in development. 103:62-70. 2010
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. 104:642-649. 2010
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. 104:118-121. 2010
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. 104:633-641. 2010
Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. 104:498-503. 2010
Safety of thrombolysis in cerebral venous thrombosis. 104:1055-1062. 2010
The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?. 104:45-48. 2010
Venous thromboembolism, age and hospitalisation: A potentially deadly combination. 104:655-656. 2010
A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo. 101:867-877. 2009
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. 101:487-494. 2009
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). 101:68-76. 2009
Advances in Understanding “High on-Treatment Platelet Reactivity”. 102:799-800. 2009
Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. 102:62-68. 2009
Are laboratories following published recommendations for lupus anticoagulant testing?. 101:178-184. 2009
Comparison of recombinant and plasma-derived antithrombin biodistribution in a rabbit model. 102:302-308. 2009
Dabigatran etexilate for prevention of venous thromboembolism. 101:2-4. 2009
Differences in prethrombin-1 activation with human or bovine factor Va can be attributed to the heavy chain. 102:623-633. 2009
Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis. 102:1212-1218. 2009
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists. 102:501-504. 2009
Pro: “Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation”. 102:912-913. 2009
Venous thromboembolism and bleeding in a community setting. 101:878-885. 2009
Venous thromboembolism in pregnancy: diagnosis, management and prevention. 101:428-438. 2009
Extended perioperative thromboprophylaxis in patients with cancer. A systematic review.. 100:1176-1180. 2008
The future management of thromboembolic disorders: Is there a need for new and improved thromboembolic treatment and management strategies?. 100:A3-A6. 2008
An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. 100:01-12. 2008
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. 99:616-622. 2008
Bivalirudin. 99:830-839. 2008
Common polymorphisms of cyclooxygenase-2 and prostaglandin E2 receptor and increased risk for acute coronary syndrome in coronary artery disease. 100:893-898. 2008
Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies – distinguishing "signal" from "noise". 100:523-524. 2008
Current use of biologicals in thrombosis and haemostasis. 99:805-806. 2008
Differences in the safety profiles of two low-molecular-weight heparins. 99:989-990. 2008
Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). 99:623-629. 2008
Extended perioperative thromboprophylaxis in patients with cancer. 100:1176-1180. 2008
Factor VIIa gets even bigger. 99:653-654. 2008
Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. 99:874-882. 2008
Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin. 99:2-3. 2008
Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. 100:1058-1067. 2008
Plasma-derived biological medicines used to promote haemostasis. 99:851-862. 2008
Propagating factor IX-producing hepatocytes for haemophilia B therapy. 99:799-800. 2008
Protective effects of activated protein C in sepsis. 100:582-592. 2008
Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting. 99:52-58. 2008
The direct thrombin inhibitor hirudin. 99:819-829. 2008
The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase. 99:511-522. 2008
Venous thromboembolism in the elderly. 100:780-788. 2008
Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin “flushes”. 98:1139-1140. 2007
Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type1 diabetic patients. 98:635-641. 2007
Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories. 98:1357-1361. 2007
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. 97:931-937. 2007
The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of α1-proteinase inhibitor M358R for thrombin. 98:1014-1023. 2007
The onerous task of comparing treatments in inhibitor patients. 98:710-712. 2007
Emerging themes in the treatment of venous thromboembolism. 96:239-241. 2006
A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. 96:802-806. 2006
Biodistribution of covalent antithrombin-heparin complexes. 95:629-636. 2006
Developmental haemostasis. 95:362-372. 2006
Emerging anticoagulants for the treatment of venous thromboembolism. 96:274-284. 2006
Emerging themes in the treatment of venous thromboembolism. 96:239-241. 2006
Initial treatment of venous thromboembolism. 96:242-250. 2006
Malignancy-associated venous thrombosis with concurrent warfarin-induced skin necrosis, venous limb gangrene and thrombotic microangiopathy. 95:1038-1039. 2006
Monitoring unfractionated heparin with the aPTT: Time for a fresh look. 96:547-552. 2006
New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. 96:258-266. 2006
Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. 96:568-577. 2006
The safety of co-administered continuous epidural analgesia and low-molecular-weight heparin after major orthopedic surgery: Assessment of a standardized patient management protocol. 96:387-389. 2006
Turnover and fate of fibrinogen and platelets at the rabbit aorta wall immediately after a balloon de-endothelializing injury in vivo. 96:60-67. 2006
Analyses of cellular multimerin 1 receptors: in vitro evidence of binding mediated by αΙΙbβ3 and αvβ3. 94:1004-1011. 2005
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. 93:1185-1188. 2005
Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. 94:750-759. 2005
Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. 94:528-531. 2005
Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. 94:132-135. 2005
Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII. 94:1177-1180. 2005
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. 94:958-964. 2005
Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. 94:1164-1171. 2005
Endocytosis and storage of plasma factor V by human megakaryocytes. 94:585-592. 2005
In vivo rabbit acute model tests of polyurethane catheters coated with a novel antithrombin-heparin covalent complex. 94:366-372. 2005
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. 93:76-79. 2005
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran. 94:522-527. 2005
Recombinant albumins containing additional peptide sequences smaller than barbourin retain the ability of barbourin-albumin to inhibit platelet aggregation. 93:914-921. 2005
Significant association with location of central venous line placement and risk of venous thrombosis in children. 94:516-521. 2005
Variability in clinical laboratory practice in testing for disorders of platelet function. 93:549-553. 2005
Ximelagatran for the secondary prevention of venous thromboembolism. 94:820-824. 2005
A case series of 72 neonates with renal vein thrombosis. 92:929-933. 2004
Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium. 91:238-247. 2004
Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin. 91:1009-1018. 2004
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist. 92:1229-1231. 2004
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. 91:1090-1096. 2004
Fondaparinux (Arixtra (R)) in the future: exploring new horizons. 91:A20-A22. 2004
Further complexities in diagnosing acquired thrombocytopenia: unexpected parallels between antibody-mediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia. 92:674-675. 2004
Human platelets contain forms of factor V in disulfide-linkage with multimerin. 92:1349-1357. 2004
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. 91:771-778. 2004
Localization of heparin and low-molecular-weight heparin in the rat kidney. 91:927-934. 2004
Systemic thromboembolism in children. 92:722-728. 2004
Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin. 92:3-12. 2004
Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. 90:364-366. 2003
Extending knowledge on inherited platelet disorders associated with thrombocytopenia. 90:770-771. 2003
Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders. 89:741-746. 2003
Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder. 90:293-298. 2003
Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins. 90:679-687. 2003
Studies of α-granule proteins in cultured human megakaryocytes. 90:844-852. 2003
Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial.. 88:48-51. 2002
Altering Heparin Cofactor II at VAL439 (P6) either Impairs Inhibition of Thrombin or Confers Elastase Resistance. 88:89-97. 2002
Anticoagulant Effect at the Time of Epidural Catheter Removal in Patients Receiving Twice-daily or Once-daily Low-molecular-weight Heparin and Continuous Epidural Analgesia after Orthopedic Surgery. 88:37-40. 2002
Decreased Concentrations of Heparinoids Are Required to Inhibit Thrombin Generation in Plasma from Newborns and Children Compared to Plasma from Adults due to Reduced Thrombin Potential. 87:606-613. 2002
Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease. 87:224-230. 2002
Electrical Foot Stimulation and Implications for the Prevention of Venous Thromboembolic Disease. 88:200-204. 2002
Low Dose Oral Vitamin K to Reverse Acenocoumarol-induced Coagulopathy: A Randomized Controlled Trial. 88:48-51. 2002
Pregnancy, Heparin and Osteoporosis. 87:180-181. 2002
The APTT Response of Pregnant Plasma to Unfractionated Heparin. 87:92-97. 2002
A 23bp Insertion in the Endothelial Protein C Receptor (EPCR) Gene Impairs EPCR Function. 86:945-948. 2001
A Barbourin-albumin Fusion Protein that Is Slowly Cleared In Vivo Retains the Ability to Inhibit Platelet Aggregation In Vitro. 86:902-908. 2001
Costs of Outpatient Anticoagulant Treatment in Patients with Cerebral and Peripheral Arterial Occlusive Disease. 85:52-56. 2001
Evidence of a Founder Effect for the Protein C Gene 3363 Inserted C Mutation in Thrombophilic Pedigrees of French Origin. 86:1000-1006. 2001
Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study. 85:390-394. 2001
Heparin-induced Thrombocytopenia: Yet Another Treatment Paradox?. 85:947-949. 2001
Like Fibrin, (DD)E, the Major Degradation Product of Crosslinked Fibrin, Protects Plasmin from Inhibition by α2-antiplasmin. 85:502-508. 2001
Low Molecular Weight Heparin Administered once versus twice Daily in Patients with Venous Thromboembolism. 86:980-984. 2001
Modification of von Willebrand Disease after Liver Transplantation. 86:1588-1589. 2001
A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. 84:805-810. 2000
A Computer Generated Induction System for Hospitalized Patients Starting on Oral Anticoagulant Therapy. 83:849-852. 2000
Adult Transient Lupus Anticoagulant Patients Maintain an Acquired Activated Protein C Resistance Profile. 84:735-736. 2000
Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. 83:416-420. 2000
Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A. 83:387-391. 2000
Mesenteric-portal Vein Thrombosis in a Patient with Hyperhomocysteinemia and Heterozygous for 20210A Prothrombin Allele. 84:358-359. 2000
Miconazole Oral Gel Potentiates Warfarin Anticoagulant Activity. 83:794-795. 2000
The Cleaved Peptide of PAR1 Results in a Redistribution of the Platelet Surface GPIb-IX-V Complex to the Surface-Connected Canalicular System. 84:897-903. 2000
Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis.. 81:879-886. 1999
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.. 81:684-689. 1999
Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread. 82:947-952. 1999
Heparin-Induced Thrombocytopenia: A Clinicopathologic Syndrome. 82:439-447. 1999
Mechanism of Action of Plasminogen Activators. 82:974-982. 1999
Most Apyrase Preparations Are Impure and Contain Inhibitors of Cathepsin G: Suggestions for Use of Apyrase in Preparation and Stabilization of Platelet Suspensions. 81:849-850. 1999
Platelet Multimerin and Its Proteolytic Processing. 82:1779-1780. 1999
Prediction of Deep Vein Thrombosis after Elective Hip Replacement Surgery by Preoperative Clinical and Haemostatic Variables: The ECAT DVT Study. 81:879-886. 1999
Safety and Efficacy of Continuous Infusion of a Combined Factor VIII – von Willebrand Factor (vWF) Concentrate (Haemate-P™) in Patients with von Willebrand Disease. 81:229-233. 1999
The Clearance of Thrombin-antithrombin and Related Serpin-enzyme Complexes from the Circulation: Role of Various Hepatocyte Receptors. 81:325-337. 1999
The Effects of Low-intensity Warfarin on Coagulation Activation in Patients with Antiphospholipid Antibodies and Systemic Lupus Erythematosus. 82:1028-1032. 1999
The Procoagulant State of the VX-2 Tumor in Rabbit Lung In Vivo. 82:1694-1702. 1999
The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene. 81:684-689. 1999
Treatment of Venous Thromboembolism. 82:870-877. 1999
Type I protein C deficiency in French Canadians: evidence of a founder effect and association of specific protein C gene mutations with plasma protein C levels.. 80:551-556. 1998
In vivo photoactivation of caged thrombin.. 80:350-351. 1998
A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of Canada. 79:872-875. 1998
Factor V Leiden and Thrombotic Complications in Heparin-induced Thrombocytopenia. 79:50-53. 1998
Heparin-induced Thrombocytopenia: Towards Consensus. 79:1-7. 1998
In Vivo Photoactivation of Caged Thrombin. 80:350-351. 1998
Low-dose Oral Vitamin K Reliably Reverses Over-anticoagulation due to Warfarin. 79:1116-1118. 1998
Morphological and Biochemical Features Affecting the Antithrombotic Properties of the Aorta in Adult Rabbits and Rabbit Pups. 79:1034-1040. 1998
No Association between the 20210 G/A Prothrombin Gene Mutation and Premature Coronary Artery Disease. 80:878-880. 1998
The Effect of Very-low-dose Warfarin on Markers of Hypercoagulation in Metastatic Breast Cancer: Results from a Randomized Trial. 79:23-27. 1998
The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. 80:413-417. 1998
The Occurrence of Subsequent Malignancy in Patients Presenting with Deep Vein Thrombosis: Results from a Historical Cohort Study. 79:19-22. 1998
Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass (vol 77, pg 270, 1997). 77:1047-1047. 1997
Rapid quantitative D-dimer assay and clinical evaluation for the diagnosis of clinically suspected deep vein thrombosis. 77:602-603. 1997
A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A. 77:660-667. 1997
Antithrombotic Therapy Following Heart Valve Replacement. 78:382-385. 1997
Coagulation and Fibrinolytic Profile of Paediatric Patients Undergoing Cardiopulmonary Bypass. 77:270-277. 1997
Erratum: Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass (Thrombosis and Haemostasis (1997) 77(2) (270-277)). 77:1047. 1997
Low Molecular Weight Heparin for the Out-of-Hospital Treatment of Venous Thrombosis: Rationale and Clinical Results. 78:689-692. 1997
Newly Diagnosed Malignancy in Patients with VenousThromboembolism. Search or Wait and See?. 78:121-125. 1997
Optimal Duration of Oral Anticoagulant Therapy in Venous Thromboembolism. 78:693-698. 1997
Pretreatment of Human Platelets with Plasmin Inhibits Responses toThrombin, but Potentiates Responses to Low Concentrations of Aggregating Agents, Including the Thrombin Receptor Activating Peptide, SFLLRN. 77:741-747. 1997
Prevention of Thrombotic Disorders in Cancer Patients Undergoing Chemotherapy. 78:133-136. 1997
The Clinical Utility of a Rapid Bedside D-dimer Assay for Screening of Deep Vein Thrombosis following Orthopaedic Surgery. 78:1300-1301. 1997
The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group.. 75:607-611. 1996
Cyclosporine Therapy for Acquired Factor VIII Inhibitor in a Patient with Systemic Lupus Erythematosus. 76:344-346. 1996
Elevated Fibrinopeptide A and B Levels during Thrombolytic Therapy: Real or Artefactual?. 75:529-535. 1996
Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism. 75:551-554. 1996
Feasibility of Using Recombinant Factor VIIa in Continuous Infusion. 75:432-436. 1996
Free Protein S Deficiency May Be Found in Patients with Antiphospholipid Antibodies who Do not Have Systemic Lupus Erythematosus. 76:689-691. 1996
Increased Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) after n-3 Polyunsaturated Fatty Acids Supplementation in Patients with Chronic Atherosclerotic Disease. 75:395-400. 1996
Low Molecular Weight Heparin and Compression Stockings in the Prevention of Venous Thromboembolism in Neurosurgery. 75:233-238. 1996
More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT. 76:0902-0908. 1996
Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis. 76:0887-0892. 1996
Probenecid Inhibits Platelet Responses to Aggregating Agents in Vitro and Has a Synergistic Inhibitory Effect with Penicillin G. 76:239-244. 1996
The Effects of Long-term Heparin Therapy During Pregnancy on Bone Density. 75:254-257. 1996
The Significance of Hypofibrinolysis for the Risk of Recurrence of Venous Thromboembolism. 75:607-611. 1996
Evaluation of a soluble fibrin assay in patients with suspected deep vein thrombosis.. 74:833-836. 1995
Advances in Antithrombotic Therapy: Novel Agents. 74:565-571. 1995
Application of a Novel and Rapid Whole Blood Assay for D-Dimer in Patients with Clinically Suspected Pulmonary Embolism. 73:035-038. 1995
Comparison of the Accuracy of Impedance Plethysmography and Compression Ultrasonography in Outpatients with Clinically Suspected Deep Vein Thrombosis. 74:1423-1427. 1995
Evaluation of a Soluble Fibrin Assay in Patients with Suspected Deep Vein Thrombosis. 74:833-836. 1995
Inhibition of Thrombin by Antithrombin III and Heparin Cofactor II In Vivo. 73:405-412. 1995
Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. 74:606-611. 1995
Platelet Accumulation on Fibrin-coated Polyethylene: Role of Platelet Activation and Factor XIII \textbar Request PDF. 73:850-856. 1995
Pre-operative Plasma Levels of Thrombin-Antithrombin III Complexes Correlate with the Development of Venous Thrombosis after Major Hip or Knee Surgery. 74:602-605. 1995
Prolonged Expression of Procoagulant Activity of Human Platelets Degranulated by Thrombin. 74:958-961. 1995
The Serological Investigation of Patients with Autoimmune Thrombocytopenia. 74:228-233. 1995
Displacement of Fibrin-bound Thrombin by r-Hirudin Precludes the Use of 131l-r-Hirudin for Detecting Pulmonary Emboli in the Rabbit. 72:232-238. 1994
Effects on Thrombin Generation of Single Injections of Hirulog™ in Patients with Calf Vein Thrombosis. 72:523-525. 1994
Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. 71:300-304. 1994
Factors Influencing the Reported Sensitivity and Specificity of Impedance Plethysmography for Proximal Deep Vein Thrombosis. 72:652-658. 1994
Heparin and Low Molecular Weight Heparins Inhibit Prothrombinase Formation but not its Activity in Plasma. 72:862-868. 1994
High Versus Ultra-high Purity Factor VIII Concentrate Therapy: Prospective Evaluation of Immunological and Clinical Parameters in HIV Seronegative and Seropositive Hemophiliacs. 72:359-362. 1994
Is Heparin the Ideal Anticoagulant for Cardiopulmonary Bypass? Dermatan Sulphate May Be an Alternate Choice. 71:468-473. 1994
Molecular Cloning and Expression of Rabbit Heparin Cofactor II: A Plasma Thrombin Inhibitor Highly Conserved between Species. 71:778-782. 1994
Monoclonal Purified F VIII for Continuous Infusion: Stability, Microbiological Safety and Clinical Experience. 72:403-407. 1994
Multicentric Evaluation of a New PT Reagent Based on Recombinant Human Tissue Factor and Synthetic Phospholipids. 71:292-299. 1994
Radiolabeled r-Hirudin as a Measure of Thrombin Activity at, or within, the Rabbit Aorta Wall In Vitro and In Vivo. 71:499-506. 1994
Recombinant Factor VIIa in Multiple Surgery. 71:154-154. 1994
Thrombin Regulation in Children Differs from Adults in the Absence and Presence of Heparin. 72:836-842. 1994
Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis.. 70:540-542. 1993
125I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients.. 69:2-7. 1993
125I-Fibrinogen Leg Scanning: Reassessment of Its Role for the Diagnosis of Venous Thrombosis in Post-Operative Patients. 69:002-007. 1993
A Significant Portion of the Aequorin Luminescent Signal from Stimulated Human and Rabbit Platelets is Due to Exposure of the Aequorin to Calcium in the Suspending Medium. 70:807-811. 1993
An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition. 69:231-235. 1993
Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. 70:625-630. 1993
Degranulation of Human Platelets by the Thrombin Receptor Peptide SFLLRN: Comparison with Degranulation by Thrombin. 70:1019-1023. 1993
Do Coagulation Screening Tests Detect Increased Generation of Thrombin and Plasmin in Sick Newborn Infants?. 69:418-421. 1993
Guidelines for Clotting Studies in Cancer Patients. 70:540-542. 1993
Low Molecular Weight Heparin. 70:204-207. 1993
The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. 70:443-447. 1993
The Effect of Antithrombin III-Independent Thrombin Inhibitors and Heparin on Fibrin Accretion onto Fibrin-Coated Polyethylene \textbar Request PDF. 69:130-134. 1993
Thrombin Generation during Cardiac Surgery: Is Heparin the Ideal Anticoagulant?. 70:259-262. 1993
Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid molar ratio in isolated platelet membranes from diabetic and control subjects.. 67:567-571. 1992
D-Dimer and Thrombin-Antithrombin III Complexes in Patients with Clinically Suspected Pulmonary Embolism. 67:408-412. 1992
Decreased Platelet Membrane Fluidity Due to Glycation or Acetylation of Membrane Proteins. 68:577-582. 1992
Fibrin Clot Lysis by Thrombolytic Agents Is Impaired in Newborns due to a Low Plasminogen Concentration. 68:325-330. 1992
Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance. 67:639-643. 1992
Lack of Stability of Aggregates after Thrombin-Induced Reaggregation of Thrombin-Degranulated Platelets. 67:453-457. 1992
Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. 67:542-544. 1992
Membrane Fluidity Is Related to the Extent of Glycation of Proteins, but not to Alterations in the Cholesterol to Phospholipid Molar Ratio in Isolated Platelet Membranes from Diabetic and Control Subjects. 67:567-571. 1992
Molecular Cloning and Cell-Free Expression of Mouse Antithrombin III. 68:291-296. 1992
Prevention of Thrombus Growth by Antithrombin III-Dependent and Two Direct Thrombin Inhibitors in Rabbits: Implications for Antithrombotic Therapy. 68:424-427. 1992
The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model. 68:064-068. 1992
Treatment of Venous Thromboembolism in Patients with Congenital Deficiency of Antithrombin III. 68:634-636. 1992
Unexpected Effects of Aurin Tricarboxylic Acid on Human Platelets. 68:189-193. 1992
Ventilation-Perfusion Lung Scanning and the Diagnosis of Pulmonary Embolism: Improvement of Observer Agreement by the Use of a Lung Segment Reference Chart. 68:245-249. 1992
Characteristics of Thrombin-Degranulated Human Platelets: Development of a Method that Does not Use Proteolytic Enzymes for Deaggregation. 65:403-410. 1991
Comparison of the Effects of Heparin and Hirudin on Thrombin Binding to the Normal and the De-Endothelialized Rabbit Aorta In Vitro. 66:208-212. 1991
Deep Vein Thrombosis: New Non-Invasive Diagnostic Tests. 66:133-137. 1991
Heparin, DDAVP and the Bleeding Time. 65:242-244. 1991
Inhibition by Ethanol of Thrombus Formation Induced by Indwelling Aortic Catheters in Rabbits. 65:454-455. 1991
Reliability of Non-Invasive Tests for the Diagnosis of Venous Thrombosis. 65:221-222. 1991
Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis. 65:541-544. 1991
The Relationship of Antiphospholipid Antibodies to Thromboembolic Disease in Systemic Lupus Erythematosus: A Cross-Sectional Study. 66:520-524. 1991
Thrombotic Complications after Substitution with a FVII Concentrate. 66:619-619. 1991
A Comparison of General Anesthesia and Regional Anesthesia as a Risk Factor for Deep Vein Thrombosis Following Hip Surgery: A Critical Review. 64:497-500. 1990
Contribution of Red Blood Cells to the Saturable Mechanism of Heparin Clearance. 64:559-563. 1990
Heparin Effect on Bone Density. 64:286-289. 1990
Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate. 63:271-274. 1990
The Antithrombotic Properties of Human Prothrombin Fragment 1.2 in Mice. 63:413-416. 1990
Thrombin Generation in Newborn Plasma Is Critically Dependent on the Concentration of Prothrombin. 63:027-030. 1990
Effect of the concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. 62:968-976. 1989
In vitro effects of ethanol on rabbit platelet aggregation, secretion of granule contents, and cyclic AMP levels in the presence of prostacyclin.. 61:254-258. 1989
Alpha-2-Macroglobulin Is an Important Progressive Inhibitor of Thrombin in Neonatal and Infant Plasma. 62:1074-1077. 1989
An Evaluation of Impedance Plethysmography and 125I-Fibrinogen Leg Scanning in Patients following Hip Surgery. 62:830-834. 1989
Effects of Sulfated Polysaccharides on Inhibition of Thrombus Formation initiated by Different Stimuli. 61:007-009. 1989
Eicosapentaenoic Acid Interferes with U46619-Stimulated Formation of Inositol Phosphates in Washed Rabbit Platelets. 62:1116-1120. 1989
In Vitro Effects of Ethanol on Rabbit Platelet Aggregation, Secretion of Granule Contents, and Cyclic AMP Levels in the Presence of Prostacyclin. 61:254-258. 1989
Risks to the Fetus of Anticoagulant Therapy During Pregnancy. 61:197-203. 1989
Risks to the Fetus of Radiologic Procedures Used in the Diagnosis of Maternal Venous Thromboembolic Disease. 61:189-196. 1989
The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement. 62:940-944. 1989
International Committee Communications. Standardization and clinical use of LMW heparin. Report of the ICTH Heparin Subcommittee, Brussels, July 1987.. 59:333. 1988
An Approach to Assigning In Vitro Potency to Unfractionated and Low Molecular Weight Heparins Based on the Inhibition of Prothrombin Activation and Catalysis of Thrombin Inhibition. 60:193-198. 1988
Antithrombotic Properties of Heparin in a Neonatal Piglet Model of Thrombin-Induced Thrombosis. 60:289-292. 1988
Conditions Affecting the Responses of Human Platelets to Epinephrine. 60:209-216. 1988
Confusion Over the Therapeutic Range for Monitoring Oral Anticoagulant Therapy in North America. 59:129-132. 1988
Effects of Ethanol on Pathways of Platelet Aggregation In Vitro. 59:383-387. 1988
Further Studies on the Mechanisms for the Antithrombotic Effects of Sulfated Polysaccharides in Rabbits. 60:188-192. 1988
Standardization and Clinical Use of LMW Heparin. 59:333-333. 1988
Catalysis of Thrombin Inhibition Provides an Index for Estimating the Antithrombotic Potential of Glycosaminoglycans in Rabbits. 57:286-293. 1987
Sample Size in the Planning and Interpretation of Clinical Trials. 58:953-956. 1987
The Basement Membrane Underlying the Vascular Endothelium Is Not Thrombogenic: In Vivo and In Vitro Studies with Rabbit and Human Tissue. 58:698-704. 1987
A Low Molecular Weight Heparin Alters the Fetal Coagulation System in the Pregnant Sheep. 55:342-346. 1986
Effects of Intermittent Pneumatic Calf Compression On Postoperative Thrombin and Plasmin Activity. 56:198-201. 1986
Immunologic Identification of the Cleavage Products from the Aα- and Bβ-Chains in the Early Stages of Plasmin Digestion of Fibrinogen. 56:100-106. 1986
A Role for Pericellular Proteoglycan in the Binding of Thrombin or Antithrombin III by the Blood Vessel Endothelium? – The Effects of Proteoglycan-Degrading Enzymes and Glycosaminoglycan-Binding Proteins on 125I-Thrombin Binding by the Rabbit Thoracic Aorta In Vitro. 53:228-234. 1985
Deaggregation of Human Platelets Aggregated by Thrombin. 53:042-044. 1985
Endothelial Cells Produce a Lipoxygenase Derived Chemo-Repellent which Influences Platelet/Endothelial Cell Interactions – Effect of Aspirin and Salicylate. 53:306-311. 1985
Epinephrine-Induced Aggregation of Rabbit Platelets Refractory to ADP. 53:366-371. 1985
Relationship Between Thromboembolic Complications and Intensity of Treatment During Long-Term Prophylaxis with Oral Anticoagulants Following DVT. 53:137-140. 1985
A Comparative Randomized Trial of Low-Dose Versus High-Dose Streptokinase in Deep Vein Thrombosis of the Thigh. 51:261-265. 1984
Effect of Amino Sugars on Platelet Aggregation and on Fibrinogen Binding. 52:075-080. 1984
Effect of Plasma Dilution on Adsorption of Fibrinogen to Solid Surfaces. 51:326-330. 1984
Effects of Tris on Responses of Human and Rabbit Platelets to Aggregating Agents. 51:140-144. 1984
Intensive Initial Oral Anticoagulation and Shorter Heparin Treatment in Deep Vein Thrombosis. 52:276-280. 1984
Uptake and Catabolism of 125l-Thrombin by the Rabbit Thoracic Aorta In Vitro: Permeability of the Endothelium, Intima-Media and Adventitial Layers. 52:105-111. 1984
Factors Influencing the Deaggregation of Chymotrypsin-Treated Human Platelets Aggregated by Fibrinogen. 49:196-198. 1983
Factors Influencing the Deaggregation of Human and Rabbit Platelets. 49:162-167. 1983
Fate of Thrombin and Thrombin-Antithrombin-III Complex Adsorbed to a Heparinized Biomaterial: Analysis of the Enzyme-Inhibitor Complexes Displaced by Plasma. 50:873-877. 1983
The Effect of Thrombin on Platelet Accumulation on the Vessel Wall - Influence of Heparin and Aspirin. 50:567-571. 1983
Inhibition of Thrombin-Neutralizing Activity of Antithrombin III by Steroid Hormones. 47:157-161. 1982
Patterns of Adsorption of Proteins From Human Plasma Onto Foreign Surfaces. 47:285-290. 1982
Thermography in the Diagnosis of DVT. 46:652-654. 1981
The Effect of Antiplatelet Drugs on Plasma Betathromboglobulin in Coronary Artery Disease. 42:059-059. 1979
Definition of High Risk/High Response Population for Stroke in Patients with Transient Ischemic Attacks. 41:43-57. 1979
International Committee Communications. 41:450-453. 1979
Prolonged Inhibition of PGI2 Production and Associatedincreased Thrombogenic Effect in Arteries After Aspirin Administration. 42:61-61. 1979
The effect of contrast media, ¹²⁵iodine-labelled fibrinogen, heparin and aspirin on plasma BTG concentration. 42:304. 1979
ACUTE FEBRILE PLEIOCHROMIC ANEMIA WITH HYALINE THROMBOSIS OF TERMINAL ARTERIOLES AND CAPILLARIES - (MOSCHCOWITZ 1925) - UNDESCRIBED DISEASE - COMMENT. 40:4-10. 1978
An Acute Febrile Pleiochromic Anemia with Hyaline Thrombosis of the Terminal Arterioles and Capillaries (Moschcowitz 1925). 40:009-010. 1978
Properties of Washed Human Platelets. 37:291-308. 1977
In Vitro and in Vivo Functions of Thrombin-Treated Platelets \textbar Request PDF. 35:151-166. 1976
Inhibition of Injury Induced Thromboatherosclerotic Lesions by Anti-Platelet Serum in Rabbits. 35:070-081. 1976
Reactions of Polylysine with Human Platelets in Plasma and in Suspensions of Washed Platelets. 36:360-375. 1976
Proceedings: Comparison of in vivo and in vitro effects of platelet function suppressing drugs.. 34:552. 1975
Proceedings: Efficacy and monitoring of heparin therapy in experimental venous thrombosis.. 34:597. 1975
Proceedings: Failure of aspirin and dipyridamole to influence the incidence of leg scan detected venous thrombosis after elective hip surgery.. 34:564. 1975
Proceedings: Heparin kinetics in venous thrombosis and pulmonary embolism.. 34:598. 1975
Proceedings: Kinetics of platelet adhesion to artificial surface in vitro.. 34:557. 1975
Proceedings: Platelet survival, fibrinolytic activity, antithrombin II (AT III) level and fibrinogen survival in venous thromboembolism (VTE).. 34:566. 1975
Proceedings: Inhibition of virus-induced platelet aggregation by treatment of platelets with neuraminidase.. 34:348. 1975
The Current Status of Platelet Suppressive Drugs in the Treatment of Thrombosis. 33:406-416. 1975
Diagnosis of thrombosis. Evaluation of 125I-fibrinogen scanning and blood tests.. 32:11-20. 1974
The interaction of platelets with polymer surfaces. I. Uncharged hydrophobic polymer surfaces.. 23:120-128. 1970
The Interaction of Platelets with Polymer Surfaces. 23:120-128. 1970
Contrasting Effects of Thrombin and the Thrombin Receptor Peptide, SFLLRN, on Aggregation and Release of 14C-Serotonin by Human Platelets Pretreated with Chymotrypsin or Serratia marcescens Protease 1995
Ticlopidine Facilitates the Deaggregation of Human Platelets Aggregated by Thrombin \textbar Request PDF 1994
ETHANOL INHIBITS RABBIT PLATELET RESPONSES TO COLLAGEN IN VITRO BUT DOES NOT AFFECT RABBIT PLATELET ADHERENCE TO DE-ENDOTHELIALIZED A0RTAE IN VIVO \textbar Request PDF 1987
IMMUNOCYTOCHEMICAL LOCALIZATION OF FIBRINOGEN DURING THROMBIN-INDUCED AGGREGATION OF HUMAN PLATELETS 1987
Arachidonate induced fibrinogen binding to thrombin degranulated platelets is independent of released ADP 1981
Comparison Of The Effects Of Aspirin And Heparin On Platelet Accumulation On The Injured Neointima Of Rabbit Aortae 1981
Injury Of Cultured Endothelial Cells By Thrombin-Stimulated Platelets 1981
The effect of phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface 1981
Vessel Injury, Thrombosis And Platelet Survival \textbar Request PDF 1981
Proceedings: The role of heparin on the inhibition of platelet adhesion to damaged arterial endothelial surface 1975

Thrombosis and Haemostasis Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)